FP045NOCTURNE: A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO COMPARE TOLVAPTAN (TLV) MODIFIED-RELEASE (MR) AND IMMEDIATE-RELEASE (IR) FORMULATIONS IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) PATIENTS (PT)

Autosomal Dominant ◽

Controlled Trial ◽

Immediate Release ◽

Phase 2 ◽

Modified Release ◽

Polycystic Kidney ◽

FP046A PHASE 2 DOSE-RANGING STUDY COMPARING PHARMACOKINETICS (PK), PHARMACODYNAMICS (PD), AND TOLERABILITY OF MODIFIED RELEASE (MR) VS IMMEDIATE RELEASE (IR) TOLVAPTAN (TLV) IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) PATIENTS (PT)

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfz106.fp046 ◽

2019 ◽

Vol 34 (Supplement_1) ◽

Author(s):

Ronald Perrone ◽

Arlene Chapman ◽

Dorothee Oberdhan ◽

Frank S Czerwiec ◽

Olga Sergeyeva ◽

...

Keyword(s):

Kidney Disease ◽

Autosomal Dominant ◽

Immediate Release ◽

Phase 2 ◽

Modified Release ◽

Polycystic Kidney ◽

Dose Ranging ◽

FP806INITIAL RESULTS FROM A PHASE 2 TRIAL OF THE SAFETY AND EFFICACY OF BARDOXOLONE METHYL IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND IGA NEPHROPATHY

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfy146.fp806 ◽

2018 ◽

Vol 33 (suppl_1) ◽

pp. i635-i635

Author(s):

Pablo Pergola ◽

Gerald Appel ◽

Ahmed Awad ◽

Geoffrey Block ◽

Melanie Chin ◽

...

Keyword(s):

Kidney Disease ◽

Iga Nephropathy ◽

Autosomal Dominant ◽

Phase 2 ◽

Polycystic Kidney ◽

Safety And Efficacy ◽

Phase 2 Trial ◽

Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial

European Journal of Pediatrics ◽

10.1007/s00431-019-03384-x ◽

2019 ◽

Vol 178 (7) ◽

pp. 1013-1021 ◽

Cited By ~ 3

Author(s):

Franz Schaefer ◽

Djalila Mekahli ◽

Francesco Emma ◽

Rodney D. Gilbert ◽

Detlef Bockenhauer ◽

...

Keyword(s):

Kidney Disease ◽

Children And Adolescents ◽

Autosomal Dominant ◽

Controlled Trial ◽

Polycystic Kidney ◽

Double Blind ◽

Double Blind Placebo ◽

Low-Osmolar Diet and Adjusted Water Intake for Vasopressin Reduction in Autosomal Dominant Polycystic Kidney Disease: A Pilot Randomized Controlled Trial

American Journal of Kidney Diseases ◽

10.1053/j.ajkd.2016.07.023 ◽

2016 ◽

Vol 68 (6) ◽

pp. 882-891 ◽

Cited By ~ 22

Author(s):

Osama W. Amro ◽

Jessica K. Paulus ◽

Farzad Noubary ◽

Ronald D. Perrone

Keyword(s):

Kidney Disease ◽

Water Intake ◽

Autosomal Dominant ◽

Controlled Trial ◽

Polycystic Kidney ◽

Randomized Controlled ◽

Autosomal Dominant Polycystic Kidney ◽

Pilot Randomized Controlled Trial

Faculty Opinions recommendation of The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.740754366.793588580 ◽

2021 ◽

Author(s):

Albert Ong ◽

Zhiguo Mao

Keyword(s):

Kidney Disease ◽

Autosomal Dominant ◽

Controlled Trial ◽

Polycystic Kidney ◽

Correction:Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD)

BMJ Open ◽

10.1136/bmjopen-2017-018794corr1 ◽

2018 ◽

Vol 8 (8) ◽

pp. e018794corr1 ◽

Cited By ~ 1

Keyword(s):

Kidney Disease ◽

Water Intake ◽

Kidney Failure ◽

Autosomal Dominant ◽

Controlled Trial ◽

Efficacy And Safety ◽

Polycystic Kidney ◽

Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): study protocol for a randomized controlled trial

Trials ◽

10.1186/s13063-015-0692-3 ◽

2015 ◽

Vol 16 (1) ◽

Cited By ~ 6

Author(s):

Markus Riegersperger ◽

Harald Herkner ◽

Gere Sunder-Plassmann

Keyword(s):

Kidney Disease ◽

Study Protocol ◽

Autosomal Dominant ◽

Controlled Trial ◽

Polycystic Kidney ◽

Randomized Controlled ◽

High Versus Ad Libitum Water Intake in Patients with Autosomal Dominant Polycystic Kidney Disease (DRINK): An Open Label, Randomised Controlled Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3294762 ◽

2018 ◽

Author(s):

Ragada El-Damanawi ◽

Michael Lee ◽

Tess Harris ◽

Laura B. Mader ◽

Simon Bond ◽

...

Keyword(s):

Kidney Disease ◽

Autosomal Dominant ◽

Phase 2 ◽

Polycystic Kidney ◽

Open Label ◽

Phase 2 Trial ◽

Ad Libitum ◽

Autosomal Dominant Polycystic Kidney ◽

Randomised Controlled

Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial

American Journal of Kidney Diseases ◽

10.1053/j.ajkd.2018.12.037 ◽

2019 ◽

Vol 74 (2) ◽

pp. 213-223 ◽

Cited By ~ 2

Author(s):

Kristen L. Nowak ◽

Berenice Gitomer ◽

Heather Farmer-Bailey ◽

Wei Wang ◽

Mikaela Malaczewski ◽

...

Keyword(s):

Kidney Disease ◽

Vascular Function ◽

Autosomal Dominant ◽

Controlled Trial ◽

Polycystic Kidney ◽

Randomized Controlled ◽

Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial

American Journal of Kidney Diseases ◽

10.1053/j.ajkd.2016.08.028 ◽

2017 ◽

Vol 69 (2) ◽

pp. 210-219 ◽

Cited By ~ 16

Author(s):

Niek F. Casteleijn ◽

Jaime D. Blais ◽

Arlene B. Chapman ◽

Frank S. Czerwiec ◽

Olivier Devuyst ◽

...

Keyword(s):

Kidney Disease ◽

Autosomal Dominant ◽

Controlled Trial ◽

Secondary Analysis ◽

Polycystic Kidney ◽

Randomized Controlled ◽